What are the indications, dosing regimen, contraindications, and monitoring requirements for Multaq (dronedarone) in patients with atrial fibrillation or atrial flutter?

Multaq (Dronedarone) for Atrial Fibrillation

Multaq (dronedarone) 400 mg twice daily with meals is indicated to reduce cardiovascular hospitalizations in patients with paroxysmal or persistent atrial fibrillation who are in sinus rhythm and have cardiovascular risk factors, but is absolutely contraindicated in permanent AF, NYHA Class IV heart failure, or recent heart failure decompensation. 1

Indications

Primary Indication:

• Reduce risk of hospitalization for atrial fibrillation in patients currently in sinus rhythm with a history of paroxysmal or persistent AF who have at least one cardiovascular risk factor 1

Appropriate Patient Population:

• Patients without significant structural heart disease as first-line rhythm control therapy 2, 3, 2
• Patients with coronary artery disease (preferred over flecainide/propafenone based on safety profile) 2
• Patients with left ventricular hypertrophy 2
• Stable NYHA Class I-II heart failure patients (LVEF >40%) 2, 4
• Patients with HFmrEF or HFpEF 5

Dosing Regimen

Standard Dose:

• 400 mg twice daily (one tablet with morning meal, one tablet with evening meal) 1

Critical Pre-Treatment Requirements:

• Stop all Class I or III antiarrhythmics before initiating dronedarone 1
• Verify females of reproductive potential are not pregnant 1
• Ensure patient is in sinus rhythm or will be cardioverted 1

Absolute Contraindications

Cardiac Contraindications:

• Permanent atrial fibrillation (doubles risk of death, stroke, and heart failure hospitalization) 6, 1
• NYHA Class IV heart failure or symptomatic heart failure with recent decompensation requiring hospitalization (doubles mortality risk) 1
• Second or third-degree AV block or sick sinus syndrome (without functioning pacemaker) 1
• Bradycardia <50 bpm 1
• QTc interval >500 ms or PR interval >280 ms 1

Drug Interactions:

• Strong CYP3A inhibitors (ketoconazole, itraconazole, voriconazole, cyclosporine, telithromycin, clarithromycin, nefazodone, ritonavir) 1
• Erythromycin 1
• Drugs that prolong QT interval (phenothiazines, tricyclic antidepressants, certain macrolides, Class I and III antiarrhythmics) 1

Other Contraindications:

• Severe hepatic impairment 1
• Prior liver or lung toxicity from amiodarone 1, 4
• Severe renal impairment (avoid if CrCl <40 mL/min; dose adjustment required for CrCl 40-60 mL/min) 4

Monitoring Requirements

Cardiac Rhythm Monitoring:

• Monitor cardiac rhythm at least every 3 months 1
• Cardiovert patients who develop AF or discontinue dronedarone 1

Hepatic Monitoring:

• Liver function tests every 3 months for the first year, then every 6 months thereafter 4
• Immediately discontinue if hepatotoxicity suspected (anorexia, nausea, vomiting, fever, malaise, fatigue, right upper quadrant pain, jaundice, dark urine, itching) 1

Baseline Assessment:

• 12-lead ECG (assess QTc and PR intervals) 7
• Liver function tests 4
• Renal function (creatinine clearance) 4
• Pregnancy test in females of reproductive potential 1

Ongoing Monitoring:

• ECG within first 6 months 7
• Serum creatinine (dronedarone moderately increases creatinine due to reduced excretion, not true renal dysfunction) 3
• Signs/symptoms of heart failure (weight gain, edema, dyspnea) 1

Clinical Efficacy Evidence

ATHENA Trial Results:

• 24% reduction in cardiovascular hospitalization or all-cause death (HR 0.76; 95% CI 0.69-0.84) 2
• 29% reduction in cardiovascular mortality (HR 0.71; 95% CI 0.51-0.98) 2
• Post-hoc analysis showed reduction in stroke risk 2
• Reduces ventricular rate during AF recurrence 3

Comparative Effectiveness:

• Less effective than amiodarone for maintaining sinus rhythm but with fewer extracardiac side effects 2, 3, 2
• Amiodarone should be reserved as second-line therapy due to toxicity profile 2, 3, 2

Critical Safety Warnings

Heart Failure Patients:

• New onset or worsening heart failure can occur even in patients with normal LV function 1
• If heart failure develops requiring hospitalization, discontinue dronedarone 1

Stroke Risk in Permanent AF:

• Increased stroke risk particularly in first two weeks of therapy in permanent AF patients 1
• Only initiate in patients in sinus rhythm receiving appropriate anticoagulation 1

Common Pitfalls to Avoid:

• Do not use dronedarone for rate control in permanent AF (increases mortality and cardiovascular events) 6
• Do not use in patients with LVEF <40% 4
• Do not combine with other Class I or III antiarrhythmics 1
• Do not use in patients with recent (within 4 weeks) heart failure decompensation 2